[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f1cfea7wz66ywj":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":23,"available_strengths":181,"label_statements":254,"drug_classes":460,"specialties":466,"medical_conditions":467,"animal_species":468},1864,"zujbotqednw1z7k52k35qf8s","flunixin",null,[],[13,19],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[24,30,36,41,46,51,55,59,65,70,75,82,87,92,96,100,104,109,113,118,123,127,131,136,140,144,149,153,158,163,170,176],{"id":25,"dose_text":26,"species":27,"administration_route":28,"limitation":10,"source_label":29},13758,"The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia, is 1.1 to 2.2 mg\u002Fkg (0.5 to 1 mg\u002Flb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg\u002Fkg (1.0 mg\u002Flb) of body weight. Avoid rapid intravenous administration of the drug. The recommended dose for acute bovine mastitis is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) of body weight given once by intravenous administration.","Cattle","Intramuscular, Intravenous","Flunine™",{"id":31,"dose_text":32,"species":27,"administration_route":33,"limitation":34,"source_label":35},13759,"1.1 to 2.2 mg\u002Fkg (0.5 to 1 mg\u002Flb; 1 to 2 mL per 100 lbs) body weight given by slow intravenous administration, either once a day as a single dose, or divided into two doses at 12-hour intervals for up to 3 days; for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia. 2.2 mg\u002Fkg (1.0 mg\u002Flb; 2 mL per 100 lbs) of body weight given once by intravenous administration for acute bovine mastitis.","Intravenous, Intramuscular","The total daily dose should not exceed 2.2 mg\u002Fkg (1.0 mg\u002Flb) of body weight. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in calves to be processed for veal. Do not use in dry dairy cows.","Flunazine™",{"id":37,"dose_text":38,"species":27,"administration_route":33,"limitation":39,"source_label":40},13760,"1. 1 to 2.2 mg\u002Fkilogram (0.5 to 1.0 mg\u002Flb) of body weight per day, as a single dose or divided into 2 doses administered at 12-hour intervals, intravenously, for up to 3 days (control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia).\n2. 2mg\u002Fkg (1.0 mg\u002Flb) of body weight given once by intravenous administration for control of pyrexia associated with acute bovine mastitis.","Do not slaughter for human consumption within 4 days of last treatment. A withdrawal period has not been established for use in preruminating calves. Do not use in calves to be processed for veal. Do not use in dry dairy cows. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Approved only for intravenous administration in cattle. Intramuscular administration has resulted in violative residues in the edible tissues of cattle sent to slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","Banamine®",{"id":42,"dose_text":43,"species":27,"administration_route":33,"limitation":44,"source_label":45},13761,"1.1 to 2.2 mg\u002Fkg (0.5 to 1.0 mg\u002Flb; 1 to 2 mL per 100 lbs) of body weight per day, as a single dose or divided into 2 doses administered at 12-hour intervals, intravenously, for up to 3 days.","Do not use in calves to be processed for veal. Do not use in dry dairy cows. Federal law restricts this drug to use by or on the order of a licensed veterinarian","Flunixin Injection",{"id":47,"dose_text":48,"species":27,"administration_route":33,"limitation":49,"source_label":50},13762,"2.2 mg\u002Fkg (1.0 mg\u002Flb; 2 mL per 100 lb) of body weight given once by intravenous administration.","Do not use in calves to be processed for veal. Do not use in dry dairy cows. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","Flunixin Meglumine Injection",{"id":52,"dose_text":53,"species":54,"administration_route":28,"limitation":10,"source_label":29},13763,"The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL\u002F100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. The recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of body weight. Intravenous administration is recommended for prompt relief. Treatment may be repeated when signs of colic recur.","Horses",{"id":56,"dose_text":57,"species":54,"administration_route":33,"limitation":58,"source_label":45},13764,"0.5 mg per pound (1mL\u002F100lbs) of body weight once daily, intravenously or intramuscularly, for up to 5 days.","Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.",{"id":60,"dose_text":61,"species":54,"administration_route":62,"limitation":63,"source_label":64},13765,"0.5 milligram of flunixin per pound of body weight (one packet per 500 pounds) per day.","Oral","Administer daily dose for up to 5 days by sprinkling on small amount of feed. The effect of this drug on pregnancy has not been determined. Not for use in horses intended for food. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","Banamine® Granules",{"id":66,"dose_text":67,"species":54,"administration_route":62,"limitation":68,"source_label":69},13766,"0.5 milligram of flunixin per pound of body weight daily.","For oral use only. Treatment should not exceed 5 consecutive days. The effect of this drug on pregnancy has not been determined. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","Banamine® Paste",{"id":71,"dose_text":72,"species":73,"administration_route":28,"limitation":58,"source_label":74},13767,"1.1 to 2.2 mg\u002Fkilogram (0.5 to 1.0 mg\u002Flb) of body weight per day, as a single dose or divided into 2 doses administered at 12-hour intervals, intravenously, for up to 3 days.","Cattle (Beef and dairy)","Flu-Nix™",{"id":76,"dose_text":77,"species":78,"administration_route":79,"limitation":80,"source_label":81},13768,"Administer 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) body weight as a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site.","Swine","Intramuscular","For intramuscular use in swine. Not tor use in breeding swine.","Flunazine®-S",{"id":83,"dose_text":84,"species":78,"administration_route":79,"limitation":85,"source_label":86},13769,"2.2 mg\u002Fkilogram (1.0 mg\u002Flb) of body weight as a single intramuscular injection.","Swine must not be slaughtered for human consumption within 12 days of last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","Banamine®-S",{"id":88,"dose_text":89,"species":10,"administration_route":90,"limitation":10,"source_label":91},13770,"DOSE AND ADMINISTRATION\n100 mL: Use within 28 days of first puncture and puncture a maximum of 19 times. If using a needle larger than 16 gauge, discard any product remaining in the vial immediately after use.\n250 mL: Use within 28 days of first puncture and puncture a maximum of 30 times. If more than 30 punctures are anticipated, the use of multi-dosing equipment is recommended. Puncture a maximum of 5 times with a dosage delivery device no larger than 4 gauge. Any product remaining beyond these parameters should be discarded.\nHorse: The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL\u002F100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.\nThe recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of body weight. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical studies approximately 10% of the horses required one or two additional treatments. The cause of colic should be determined and treated with concomitant therapy.\nCattle: The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia is 1.1 to 2.2 mg\u002Fkg (0.5 to 1.0 mg\u002Flb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg\u002Fkg (1.0 mg\u002Flb) of body weight. Avoid rapid intravenous administration of the drug.\nThe recommended dose for acute bovine mastitis is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) of body weight given once by intravenous administration.","INTRAVENOUS, INTRAMUSCULAR","FDA application 200-387",{"id":93,"dose_text":94,"species":10,"administration_route":95,"limitation":10,"source_label":91},13771,"DOSE AND ADMINISTRATION\nUse within 28 days of first puncture and puncture a maximum of 30 times. If more than 30 punctures are anticipated, the use of multi-dosing equipment is recommended. Puncture a maximum of 5 times with a dosage delivery device no larger than 4 gauge. Any product remaining beyond these parameters should be discarded.\nHorse: The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL\u002F100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.\nThe recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of body weight. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical studies approximately 10% of the horses required one or two additional treatments. The cause of colic should be determined and treated with concomitant therapy.\nCattle: The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia is 1.1 to 2.2 mg\u002Fkg (0.5 to 1.0 mg\u002Flb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg\u002Fkg (1.0 mg\u002Flb) body weight. Avoid rapid intravenous administration of the drug.\nThe recommended dose for acute bovine mastitis is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) of body weight given once by intravenous administration.","INTRAMUSCULAR, INTRAVENOUS",{"id":97,"dose_text":98,"species":10,"administration_route":90,"limitation":10,"source_label":99},13772,"USE WITHIN 28 DAYS OF FIRST PUNCTURE AND PUNCTURE A MAXIMUM OF 10 TIMES FOR 100 ML FILL, 25 TIMES FOR 250 ML FILL AND 50 TIMES FOR 500 ML FILL. WHEN USING A DRAW-OFF SPIKE, DISCARD ANY PRODUCT REMAINING IN THE VIAL IMMEDIATELY AFTER USE.\nHorse:\nThe recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL\u002F100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.\nThe recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of body weight. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical studies approximately 10% of the horses required one or two additional treatments. The cause of colic should be determined and treated with concomitant therapy.\nCattle: The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia, is 1.1 to 2.2 mg\u002Fkg (0.5 to 1 mg\u002Flb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg\u002Fkg (1.0 mg\u002Flb) of body weight. Avoid rapid intravenous administration of the drug.\nThe recommended dose for acute bovine mastitis is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 ml per 100 lbs) of body weight given once by intravenous administration.","FDA application 200-781",{"id":101,"dose_text":102,"species":10,"administration_route":90,"limitation":10,"source_label":103},13773,"Dose and Administration\nHorse:\nThe recommended dose for musculoskeletal disorders is 0.5 mg per pound (1\nmL\u002F100 lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular\ninjection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak\nresponse occurs between 12 and 16 hours. Peak response occurs between 12 and 16 hours and\nduration of activity is 24-36 hours.\nThe recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound\nof body weight. Intravenous administration is recommended for prompt relief. Clinical studies\nshow pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when\nsigns of colic recur. During clinical studies approximately 10% of the horses required one or\ntwo additional treatments. The cause of colic should be determined and treated with\nconcomitant therapy.\nCattle:\nThe recommended dose for control of pyrexia associated with bovine respiratory\ndisease and endotoxemia and control of inflammation in endotoxemia is 1.1 to 2.2 mg\u002Fkg\n(0.5 to 1 mg\u002Flb;1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration\neither once a day as a single dose or divided into two doses administered at 12-hour intervals for\nup to 3 days. The total daily dose should not exceed 2.2 mg\u002Fkg (1.0 mg\u002Flb) of body weight.\nAvoid rapid intravenous administration of the drug.\nThe recommended dose for acute bovine mastitis is 2.2 mg\u002Fkg (1.0 mg\u002Flb; 2 mL per 100 lbs) of body\nweight given once by intravenous administration.","FDA application 200-061",{"id":105,"dose_text":106,"species":10,"administration_route":107,"limitation":10,"source_label":108},13774,"DOSAGE AND ADMINISTRATION: The recommended dose of flunixin meglumine is 0.5 mg per lb of body weight once daily. The VetaMeg Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.\nDOSAGE TABLE\nSyringe Mark*\nHorse Weight (lbs)\nVetaMeg™ Equine Paste Delevered (g)\nmg Flunixin Delivered\n0\n---\n---\n---\n250\n250\n2.5\n125\n500\n500\n5.0\n250\n750\n750\n7.5\n375\n1000\n1000\n10.0\n500\n* Use dial edge nearest syringe barrel to mark dose.\nThe paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.\nTreatment may be given initially by intravenous or intramuscular injection of VetaMeg Injectable Solution, followed by VetaMeg Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.\nTOXICITY: No toxic effects were observed in rats given oral flunixin meglumine 2 mg\u002Fkg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg\u002Fkg. Flunixin was well tolerated in monkeys dosed daily with 4 mg\u002Fkg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg\u002Flb for 5 consecutive days.","ORAL","FDA application 200-581",{"id":110,"dose_text":111,"species":10,"administration_route":107,"limitation":10,"source_label":112},13775,"DOSAGE AND ADMINISTRATION The recommended dose of flunixin is 0.5 mg per lb of body weight once daily. The BANAMINE Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.\nDOSAGE TABLE\nSyringe MarkUse dial edge nearest syringe barrel to mark dose.\nHorse Weight (lbs)\nBANAMINE Paste Delivered (g)\nMg Flunixin Delivered\n0\n—\n—\n—\n250\n250\n2.5\n125\n500\n500\n5.0\n250\n750\n750\n7.5\n375\n1000\n1000\n10.0\n500\nThe paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.\nTreatment may be given initially by intravenous or intramuscular injection of BANAMINE Solution, followed by BANAMINE Granules or BANAMINE Paste on Days 2 to 5. BANAMINE treatment should not exceed 5 consecutive days.","Banamine® (flunixin meglumine paste)",{"id":114,"dose_text":115,"species":10,"administration_route":116,"limitation":10,"source_label":117},13776,"DOSAGE AND ADMINISTRATION\nThe recommended dose for swine is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) body weight given by a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site.\n100 mL: Use within 28 days of first puncture and puncture a maximum of 19 times. If using a needle larger than 16 gauge, discard any remaining product in the vial immediately after use.\n250 mL: Use within 28 days of first puncture and puncture a maximum of 30 times with a needle or 5 times with a dosage delivery device. If using a needle larger than 4 gauge, discard any remaining product in the vial immediately after use.\nNote: Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.","INTRAMUSCULAR","FDA application 200-489",{"id":119,"dose_text":120,"species":10,"administration_route":121,"limitation":10,"source_label":122},13777,"DOSAGE AND ADMINISTRATION: Apply only once at a dose of 3.3 mg flunixin per kg body weight (1.5 mg\u002Flb; 3 mL per 100 lbs) topically in a narrow strip along the dorsal midline from the withers to the tailhead. Round the dose up to the nearest weight increment on the dosing chamber. If pyrexia, or the pain associated with foot rot persists, the diagnosis should be re-evaluated and alternative therapy considered. Do not treat cattle if the hide is wet or may get wet in the six hours after dosing because effectiveness has not been evaluated under wet hide conditions.\nPractice the Administration and Overfill Reduction Instructions a few times to become familiar with operating the package before dosing animals.\nIf the dosing chamber is overfilled follow the Overfill Reduction Instructions.\nA small amount of liquid will remain on the walls of the chamber, but the chamber is calibrated to account for this.","TRANSDERMAL","Banamine® Transdermal(flunixin transdermal solution)",{"id":124,"dose_text":125,"species":10,"administration_route":95,"limitation":10,"source_label":126},13778,"Horse: The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL\u002F100 lbs) of bodyweight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to five days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.\nThe recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of bodyweight. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical studies approximately 10% of the horses required one or two additional treatments. The cause of the colic should be determined and treated with concomitant therapy.","covetrus® Flunixin Injection(flunixin meglumine injection)50 mg\u002Fml",{"id":128,"dose_text":129,"species":10,"administration_route":116,"limitation":10,"source_label":130},13779,"The recommended dose for swine is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) body weight given by a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site.\nUSE WITHIN 28 DAYS OF FIRST PUNCTURE AND PUNCTURE A MAXIMUM OF 10 TIMES. WHEN USING A DRAW-OFF SPIKE OR NEEDLE WITH BORE DIAMETER LARGER THAN 18 GAUGE, DISCARD ANY PRODUCT REMAINING IN THE VIAL IMMEDIATELY AFTER USE.\nNote: Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.","Banamine®-S (flunixin meglumine injection)",{"id":132,"dose_text":133,"species":10,"administration_route":134,"limitation":10,"source_label":135},13780,"DOSAGE AND ADMINISTRATION: RESFLOR GOLD® should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol\u002Fkg body weight and 2.2 mg flunixin\u002Fkg body weight (6 mL\u002F100 lb). Do not administer more than 10 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. For the 500 mL vial, do not puncture the stopper more than 20 times.\nRESFLOR GOLD® Dosage GuideDo not administer more than 10 mL at each site.\nANIMAL WEIGHT\n(lbs)\nDOSAGE\n(mL)\n100\n6.0\nRecommended Injection Location\n200\n12.0\n300\n18.0\n400\n24.0\n500\n30.0\n600\n36.0\n700\n42.0\n800\n48.0\n900\n54.0\n1000\n60.0","SUBCUTANEOUS","Resflor GOLD®",{"id":137,"dose_text":138,"species":10,"administration_route":116,"limitation":10,"source_label":139},13781,"The recommended dose for swine is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) body weight given by a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site.\nNote: Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection.\nThis may result in trim loss of edible tissue at slaughter.","Flunixin Injection -S(flunixin meglumine injection)50 mg\u002FmLFor intramuscular use in swine.",{"id":141,"dose_text":142,"species":10,"administration_route":134,"limitation":10,"source_label":143},13782,"nixiFLOR™ should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol\u002Fkg body weight and 2.2 mg flunixin\u002Fkg body weight (6 mL\u002F100 lb). Do not administer more than 10 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. For the 500 mL vial, do not puncture the stopper more than 20 times.\n* Do not administer more than 10 mL at each site.","nixiFLOR™(florfenicol and flunixin meglumine)Antimicrobial\u002FNon-Steroidal Anti-Inflammatory Drug",{"id":145,"dose_text":146,"species":10,"administration_route":79,"limitation":147,"source_label":148},13783,"The recommended dose for swine is 2.2 mg\u002Fkg (1 mg\u002Flb; 2 mL per 100 lbs) body weight given by a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site","Not for use in breeding swine. Federal law restricts this drug to use by or on the order of a licensed veterinarian.","Flunixin Injection - S",{"id":150,"dose_text":151,"species":10,"administration_route":90,"limitation":10,"source_label":152},13784,"USE WITHIN 28 DAYS OF FIRST PUNCTURE AND PUNCTURE A MAXIMUM OF 10 TIMES. WHEN USING A DRAW-OFF SPIKE OR NEEDLE WITH BORE DIAMETER LARGER THAN 18 GAUGE, DISCARD ANY PRODUCT REMAINING IN THE VIAL IMMEDIATELY AFTER USE.","Banamine® (flunixin meglumine injection)",{"id":154,"dose_text":155,"species":10,"administration_route":62,"limitation":156,"source_label":157},13785,"0.5 mg per pound of body weight per day for up to 5 days","For oral use in horses only. Treatment should not exceed 5 consecutive days. The effect of flunixin meglumine on pregnancy has not been determined. Federal law restricts this drug to use by or on the order of a licensed veterinarian","Flunazine®",{"id":159,"dose_text":160,"species":161,"administration_route":162,"limitation":10,"source_label":135},13786,"Administer once by subcutaneous injection at a dose rate of 40 mg florfenicol\u002Fkg body weight and 2.2 mg flunixin\u002Fkg body weight (6 mL\u002F100 lb).","Cattle (Beef and Non-Lactating Dairy)","Subcutaneous",{"id":164,"dose_text":165,"species":166,"administration_route":167,"limitation":168,"source_label":169},13787,"Administer once as an intramuscular or subcutaneous injection of 1 mL per 22 pounds (lb) body weight (BW) (13.6 mg oxytetracycline and 0.9 mg flunixin per lb BW) where retreatment of calves and yearlings for bacterial pneumonia is impractical due to husbandry conditions, such as cattle on range, or where their repeated restraint is inadvisable","Cattle (Beef, Non-Lactating Dairy, Calves, Yearlings)","Intramuscular, Subcutaneous","Federal law restricts this drug to use by or on the order of a licensed veterinarian.\nFor intramuscular or subcutaneous use in beef and non-lactating dairy cattle, calves and yearlings.\nNot for use in female dairy cattle 20 months of age or older, including dry dairy cows, bulls intended for breeding, and calves intended to be processed for veal.\nDo not use in animals showing hypersensitivity to either flunixin meglumine or oxytetracycline.","Hexasol® Injection",{"id":171,"dose_text":172,"species":173,"administration_route":174,"limitation":10,"source_label":175},13788,"Apply only once at a dose of 3.3 mg flunixin per kg body weight (1.5 mg\u002Flb; 3 mL per 100 lbs) topically in a narrow strip along the dorsal midline from the withers to the tailhead.","Cattle (beef cattle 2 months of age and older and dairy cattle. Not for use in beef and dairy bulls intended for breeding over 1 year of age, replacement dairy heifers over 20 months of age, dry dairy cows, dairy calves, or veal calves)","Transdermal","Banamine® Transdermal",{"id":177,"dose_text":178,"species":179,"administration_route":162,"limitation":10,"source_label":180},13789,"40 mg florfenicol\u002Fkg body weight (BW) and 2.2 mg flunixin\u002Fkg BW (equivalent to 2 mL\u002F15 kg BW or 6 mL\u002F100 lbs) once, by subcutaneous injection.","Beef and non-lactating dairy cattle","nixiFLOR™",[182,186,188,191,193,197,199,201,205,207,209,211,213,217,220,223,226,230,233,237,239,241,245,248,251],{"id":183,"strength_text":184,"dosage_form":185,"proprietary_name":35,"species":27,"source_label":35},11957,"Each mL of solution contains flunixin meglumine equivalent to 50 mg flunixin.","Liquid (Solution)",{"id":187,"strength_text":184,"dosage_form":185,"proprietary_name":35,"species":54,"source_label":35},11958,{"id":189,"strength_text":190,"dosage_form":185,"proprietary_name":74,"species":54,"source_label":74},11959,"Each mL contains flunixin meglumine equivalent to 50 mg flunixin.",{"id":192,"strength_text":190,"dosage_form":185,"proprietary_name":74,"species":73,"source_label":74},11960,{"id":194,"strength_text":195,"dosage_form":185,"proprietary_name":196,"species":54,"source_label":196},11961,"The drug contains 50 milligrams of flunixin per milliliter of aqueous solution.","Flunixin Meglumine Solution",{"id":198,"strength_text":184,"dosage_form":185,"proprietary_name":50,"species":54,"source_label":50},11962,{"id":200,"strength_text":184,"dosage_form":185,"proprietary_name":50,"species":27,"source_label":50},11963,{"id":202,"strength_text":203,"dosage_form":204,"proprietary_name":45,"species":54,"source_label":45},11964,"Each milliliter of solution contains flunixin meglumine equivalent to 50 mg flunixin.","Injectable Solution",{"id":206,"strength_text":203,"dosage_form":204,"proprietary_name":45,"species":27,"source_label":45},11965,{"id":208,"strength_text":195,"dosage_form":204,"proprietary_name":40,"species":54,"source_label":40},11966,{"id":210,"strength_text":195,"dosage_form":204,"proprietary_name":40,"species":27,"source_label":40},11967,{"id":212,"strength_text":195,"dosage_form":204,"proprietary_name":86,"species":78,"source_label":86},11968,{"id":214,"strength_text":215,"dosage_form":216,"proprietary_name":64,"species":54,"source_label":64},11969,"Each 10-gram packet contains flunixin meglumine equivalent to 250 milligrams of flunixin.","Top Dressing In Feed",{"id":218,"strength_text":219,"dosage_form":204,"proprietary_name":81,"species":78,"source_label":81},11970,"Each milliliter contains flunixin meglumine equivalent to 50 mg of flunixin.",{"id":221,"strength_text":222,"dosage_form":204,"proprietary_name":135,"species":161,"source_label":135},11971,"300 mg florfenicol and 16.5 mg flunixin as flunixin meglumine",{"id":224,"strength_text":225,"dosage_form":185,"proprietary_name":169,"species":166,"source_label":169},11972,"300 mg oxytetracycline and 20 mg flunixin base as flunixin meglumine per mL.",{"id":227,"strength_text":228,"dosage_form":229,"proprietary_name":157,"species":10,"source_label":157},11973,"30 grams of paste contains flunixin meglumine equivalent to 1,500 mg of flunixin.","Paste",{"id":231,"strength_text":232,"dosage_form":229,"proprietary_name":69,"species":54,"source_label":69},11974,"Each 30-gram syringe contains flunixin meglumine equivalent to 1,500 milligrams of flunixin.",{"id":234,"strength_text":235,"dosage_form":236,"proprietary_name":175,"species":173,"source_label":175},11975,"50 mg\u002FmL","Solution",{"id":238,"strength_text":235,"dosage_form":204,"proprietary_name":29,"species":54,"source_label":29},11976,{"id":240,"strength_text":235,"dosage_form":204,"proprietary_name":29,"species":27,"source_label":29},11977,{"id":242,"strength_text":243,"dosage_form":204,"proprietary_name":244,"species":78,"source_label":244},11978,"50 mg flunixin (equivalent to 83 mg flunixin meglumine) per mL","Flunine-S™",{"id":246,"strength_text":247,"dosage_form":204,"proprietary_name":180,"species":179,"source_label":180},11979,"300 mg florfenicol and 16.5 mg flunixin (as flunixin meglumine) per mL",{"id":249,"strength_text":250,"dosage_form":10,"proprietary_name":10,"species":10,"source_label":139},11980,"50 mg \u002F 1 mL",{"id":252,"strength_text":253,"dosage_form":10,"proprietary_name":10,"species":10,"source_label":108},11981,"1500 mg \u002F 30 g",[255,259,262,265,268,271,274,277,280,283,286,289,292,295,298,301,304,307,310,313,316,319,322,325,328,331,334,336,339,342,345,348,352,355,358,361,364,367,370,374,377,380,383,386,389,392,395,398,401,404,407,410,414,417,420,423,426,429,432,435,438,441,445,448,451,454,457],{"id":256,"kind":257,"statement":258,"species":27,"limitation":10,"source_label":29},20187,"indication","For the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. It is also indicated for the control of inflammation in endotoxemia.",{"id":260,"kind":257,"statement":261,"species":27,"limitation":44,"source_label":45},20188,"For control of pyrexia associated with bovine respiratory disease, acute bovine mastitis, and endotoxemia. Also indicated for the control of inflammation in endotoxemia.",{"id":263,"kind":257,"statement":264,"species":27,"limitation":34,"source_label":35},20189,"For the control of pyrexia associated with bovine respiratory disease, endotoxemia, and acute bovine mastitis.",{"id":266,"kind":257,"statement":267,"species":27,"limitation":49,"source_label":50},20190,"For control of pyrexia associated with acute bovine mastitis.",{"id":269,"kind":257,"statement":270,"species":54,"limitation":10,"source_label":29},20191,"For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.",{"id":272,"kind":257,"statement":273,"species":54,"limitation":58,"source_label":45},20192,"For the alleviation of inflammation and pain associated with musculoskeletal disorders and the alleviation of visceral pain associated with colic.",{"id":275,"kind":257,"statement":276,"species":54,"limitation":63,"source_label":64},20193,"For alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.",{"id":278,"kind":257,"statement":279,"species":73,"limitation":58,"source_label":74},20194,"For control of pyrexia associated with bovine respiratory disease, endotoxemia, and acute bovine mastitis. It is also indicated for the control of inflammation in endotoxemia.",{"id":281,"kind":257,"statement":282,"species":78,"limitation":85,"source_label":86},20195,"For the control of pyrexia associated with swine respiratory disease.",{"id":284,"kind":257,"statement":285,"species":10,"limitation":10,"source_label":108},20196,"INDICATIONS: Flunazine Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.\nACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.",{"id":287,"kind":257,"statement":288,"species":10,"limitation":10,"source_label":108},20197,"INDICATIONS: Prevail Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.\nACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show 1 onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.",{"id":290,"kind":257,"statement":291,"species":10,"limitation":10,"source_label":103},20198,"Indications\nHorse:\nFlunixin Injection (flunixin meglumine injection) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.\nCattle:\nFlunixin Injection (flunixin meglumine injection) is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. Flunixin Injection (flunixin meglumine injection) is also indicated for the control of inflammation in endotoxemia.",{"id":293,"kind":257,"statement":294,"species":10,"limitation":10,"source_label":103},20199,"Indications\nHorse:\nFlu-Nix™ (flunixin meglumine injection) is recommended for the alleviation of\ninflammation and pain associated with musculoskeletal disorders in the horse. It is also\nrecommended for the alleviation of visceral pain associated with colic in the horse.\nCattle:\nFlu-Nix™ (flunixin meglumine injection) is indicated for the control of pyrexia associated\nwith bovine respiratory disease, endotoxemia and acute bovine mastitis. Flu-Nix™ (flunixin\nmeglumine injection) is also indicated for the control of inflammation in endotoxemia.",{"id":296,"kind":257,"statement":297,"species":10,"limitation":10,"source_label":91},20200,"INDICATIONS\nHorse: Flunazine (flunixin meglumine injection) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.\nCattle: Flunazine (flunixin meglumine injection) is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. Flunazine is also indicated for the control of inflammation in endotoxemia.",{"id":299,"kind":257,"statement":300,"species":10,"limitation":10,"source_label":91},20201,"INDICATIONS\nHorse: Vetameg (flunixin meglumine injection) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.\nCattle: Vetameg (flunixin meglumine injection) is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. Vetameg is also indicated for the control of inflammation in endotoxemia.",{"id":302,"kind":257,"statement":303,"species":10,"limitation":10,"source_label":122},20202,"INDICATIONS: Banamine Transdermal pour-on is indicated for the control of pyrexia associated with bovine respiratory disease and acute bovine mastitis, and the control of pain associated with foot rot in beef cattle 2 months of age and older and dairy cattle.\nNot for use in beef and dairy bulls intended for breeding over 1 year of age, replacement dairy heifers over 20 months of age, dry dairy cows, dairy calves, or veal calves.",{"id":305,"kind":257,"statement":306,"species":10,"limitation":10,"source_label":103},20203,"Only for Intravenous use in Beef and Dairy Cattle.\nNot for Use in Dry Dairy Cows and Veal Calves. For\nIntravenous and Intramuscular Use in Horses.\nRead accompanying directions for use.\nApproved by FDA under ANADA # 200-061\n®Registered trademark of Huvepharma, Inc.\nManufactured for\nHuvepharma, Inc.\nPeachtree City, GA 30269\nRev. 05-2022 F-2847-05",{"id":308,"kind":257,"statement":309,"species":10,"limitation":10,"source_label":152},20204,"INDICATIONS\nHorse: BANAMINE (flunixin meglumine injection) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.",{"id":311,"kind":257,"statement":312,"species":10,"limitation":10,"source_label":135},20205,"INDICATION: RESFLOR GOLD® is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.",{"id":314,"kind":257,"statement":315,"species":10,"limitation":10,"source_label":143},20206,"nixiFLOR™ is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.",{"id":317,"kind":257,"statement":318,"species":10,"limitation":10,"source_label":103},20207,"Only for Intravenous Use in Beef and Dairy Cattle.\nNot for Use in Dry Dairy Cows and Veal Calves. For Intravenous\nand Intramuscular use in Horses.\nBefore using this drug, read package outsert for complete\nproduct information.",{"id":320,"kind":257,"statement":321,"species":10,"limitation":10,"source_label":103},20208,"Only for Intravenous use in Beef and Dairy Cattle. Not for Use\nin Dry Dairy Cows and Veal Calves. For Intravenous and\nIntramuscular Use in Horses.\nRead accompanying directions for use.",{"id":323,"kind":257,"statement":324,"species":10,"limitation":10,"source_label":103},20209,"Only for Intravenous Use in Beef and Dairy Cattle.\nNot for Use in Dry Dairy Cows and Veal Calves.\nFor Intravenous and Intramuscular Use in Horses.",{"id":326,"kind":257,"statement":327,"species":10,"limitation":10,"source_label":112},20210,"INDICATIONS BANAMINE Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.",{"id":329,"kind":257,"statement":330,"species":10,"limitation":10,"source_label":117},20211,"INDICATION\nFlunazine-S (flunixin meglumine injection) is indicated for the control of pyrexia associated with swine respiratory disease.",{"id":332,"kind":257,"statement":333,"species":10,"limitation":156,"source_label":157},20212,"For the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse",{"id":335,"kind":257,"statement":282,"species":10,"limitation":147,"source_label":148},20213,{"id":337,"kind":257,"statement":338,"species":161,"limitation":10,"source_label":135},20214,"For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non lactating dairy cattle.",{"id":340,"kind":257,"statement":341,"species":166,"limitation":168,"source_label":169},20215,"For the treatment of bacterial pneumonia associated with Pasteurella spp. and for the control of associated pyrexia in beef and non-lactating dairy cattle",{"id":343,"kind":257,"statement":344,"species":173,"limitation":10,"source_label":175},20216,"For the control of pyrexia associated with bovine respiratory disease and acute bovine mastitis, and the control of pain associated with foot rot.",{"id":346,"kind":257,"statement":347,"species":179,"limitation":10,"source_label":180},20217,"For treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.",{"id":349,"kind":350,"statement":351,"species":10,"limitation":10,"source_label":91},20218,"contraindication","CONTRAINDICATIONS\nHorse: There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverse reactions. Signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to flunixin meglumine.\nCattle: NSAIDS inhibit production of prostaglandins which are important in signaling the initiation of parturition. The use of flunixin can delay parturition and prolong labor which may increase the risk of still birth. Do not use Flunixin Injection (flunixin meglumine injection) within 48 hours of expected parturition. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration are suspected.",{"id":353,"kind":350,"statement":354,"species":10,"limitation":10,"source_label":152},20219,"CONTRAINDICATIONS\nHorse: There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverse reactions. Signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to flunixin meglumine.",{"id":356,"kind":350,"statement":357,"species":10,"limitation":10,"source_label":122},20220,"CONTRAINDICATIONS: NSAIDs inhibit production of prostaglandins which are important in signaling the initiation of parturition. The use of flunixin can delay parturition and prolong labor which may increase the risk of stillbirth. Do not use Banamine Transdermal pour-on within 48 hours of expected parturition. Do not use in animals showing hypersensitivity to flunixin meglumine.",{"id":359,"kind":350,"statement":360,"species":10,"limitation":10,"source_label":117},20221,"CONTRAINDICATIONS\nThere are no known contraindications to this drug in swine when used as directed. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration is suspected.",{"id":362,"kind":350,"statement":363,"species":10,"limitation":10,"source_label":135},20222,"CONTRAINDICATIONS: Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.",{"id":365,"kind":350,"statement":366,"species":10,"limitation":10,"source_label":112},20223,"CONTRAINDICATIONS There are no known contraindications to this drug when used as directed.",{"id":368,"kind":350,"statement":369,"species":10,"limitation":10,"source_label":143},20224,"Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.",{"id":371,"kind":372,"statement":373,"species":10,"limitation":10,"source_label":108},20225,"warning","VetaMeg® Equine Paste\n(flunixin meglumine paste)\nCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.\nDESCRIPTION: Each 30-g syringe of VetaMeg Equine Paste contains flunixin meglumine equivalent to 1500 mg flunixin.\nINDICATIONS: VetaMeg Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.\nACTIVITY: Flunixin meglumine is a potent, nonnarcotic, nonsteroidal analgesic agent with anti-inflammatory and antipyretic activity, It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs withing 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.\nCONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.\nWARNING: Do not use in horses intended for human consumption.\nPRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.\nSIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Aspen Veterinary Resources at info@aspenveterinaryresources.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov\u002Freportanimalae.",{"id":375,"kind":372,"statement":376,"species":10,"limitation":10,"source_label":122},20226,"USER SAFETY WARNINGS: Not for use in humans. Keep out of reach of children. Flunixin transdermal solution is a potent non-steroidal anti-inflammatory drug (NSAID), and ingestion may cause gastrointestinal irritation and bleeding, kidney, and central nervous system effects.\nThis product has been shown to cause severe and potentially irreversible eye damage (conjunctivitis, iritis, and corneal opacity) and irritation to skin in laboratory animals. Users should wear suitable eye protection (face shields, safety glasses, or goggles) to prevent eye contact; and chemical resistant gloves and appropriate clothing (such as long-sleeve shirt and pants) to prevent skin contact and\u002For drug absorption. Wash hands after use.\nIn case of accidental eye contact, flush eyes immediately with water and seek medical attention. If wearing contact lenses, flush eyes immediately with water before removing lenses. In case of accidental skin contact and\u002For clothing contamination, wash skin thoroughly with soap and water and launder clothing with detergent. In case of ingestion do not induce vomiting and seek medical attention immediately. Probable mucosal damage may contraindicate the use of gastric lavage. Provide product label and\u002For package insert to medical personnel.",{"id":378,"kind":372,"statement":379,"species":10,"limitation":10,"source_label":91},20227,"SAFETY\nHorse: A 3-fold intramuscular dose of 1.5 mg\u002Flb of body weight daily for 10 consecutive days was safe. No changes were observed in hematology, serum chemistry, or urinalysis values. Intravenous dosages of 0.5 mg\u002Flb daily for 15 days; 1.5 mg\u002Flb daily for 10 days; and 2.5 mg\u002Flb daily for 5 days produced no changes in blood or urine parameters. No injection site irritation was observed following intramuscular injection of the 0.5 mg\u002Flb recommended dose. Some irritation was observed following a 3-fold dose administered intramuscularly.\nCattle: No flunixin-related changes (adverse reactions) were noted in cattle administered a 1X (2.2 mg\u002Fkg; 1.0 mg\u002Flb) dose for 9 days three times the maximum clinical duration. Minimal toxicity manifested itself at moderately elevated doses (3X and 5X) when flunixin was administered daily for 9 days, with occasional findings of blood in the feces and\u002For urine. Discontinue use if hematuria or fecal blood are observed.",{"id":381,"kind":372,"statement":382,"species":10,"limitation":10,"source_label":108},20228,"For oral use in horses only\nCONTRAINDICATIONS: There are no known contraindications to this drug when used as directed.\nWARNING: Do not use in horses intended for human consumption.\nPRECAUTIONS: The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.\nSIDE EFFECTS: During field studies with flunixin meglumine, no significant side effects were reported.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VET or online at www.fda.gov\u002Freportanimalaeduration of activity is 24 to 36 hours.",{"id":384,"kind":372,"statement":385,"species":10,"limitation":10,"source_label":143},20229,"WARNINGS: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN.\nThis product contains material that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Safety Data Sheet (SDS) contains more detailed occupational safety information. For customer service, adverse effects reporting, and\u002For a copy of the SDS, contact Parnell at 1-800-887-2763. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",{"id":387,"kind":372,"statement":388,"species":10,"limitation":10,"source_label":143},20230,"A target animal safety study was conducted to evaluate the effects of florfenicol and flunixin meglumine when administered to cattle subcutaneously at 1X, 3X, or 5X the labeled dose for three consecutive days (3X the labeled duration). Decreased feed and water consumption, and decreased body weights (secondary to decreased feed consumption) were observed in the 1X, 3X, and 5X groups. Injection site swellings were noted in the 1X, 3X, and 5X groups.\nA separate injection site study was conducted in cattle. The study demonstrated that florfenicol and flunixin meglumine, when administered according to the label directions, may induce a transient local reaction in the subcutaneous and underlying muscle tissue.",{"id":390,"kind":372,"statement":391,"species":10,"limitation":10,"source_label":122},20231,"Withdrawal Periods and Residue Warnings:\nMilk that has been taken during treatment and for 48 hours after treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 8 days of treatment. Not for use in replacement dairy heifers 20 months of age or older or dry dairy cows; use in these cattle may cause drug residues in calves born to these cows or heifers. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Approved only as a single topical dose in cattle. Repeated treatments may result in violative residues in milk or in edible tissues.",{"id":393,"kind":372,"statement":394,"species":10,"limitation":10,"source_label":91},20232,"RESIDUE WARNINGS: Cattle must not be slaughtered for human consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Not for use in dry dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Not for use in horses intended for food. Approved only for intravenous administration in cattle. Intramuscular administration has resulted in violative residues in the edible tissues of cattle sent to slaughter.",{"id":396,"kind":372,"statement":397,"species":10,"limitation":10,"source_label":135},20233,"RESIDUE WARNINGS: Animals intended for human consumption must not be slaughtered within 38 days of treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and\u002For in calves born to these cows. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal.",{"id":399,"kind":372,"statement":400,"species":10,"limitation":10,"source_label":143},20234,"For subcutaneous use in beef and non-lactating dairy cattle only.\nNot for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.\nCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.",{"id":402,"kind":372,"statement":403,"species":10,"limitation":10,"source_label":117},20235,"RESIDUE WARNINGS\nSwine must not be slaughtered for human consumption within 12 days of the last treatment.",{"id":405,"kind":372,"statement":406,"species":10,"limitation":10,"source_label":112},20236,"CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.",{"id":408,"kind":372,"statement":409,"species":10,"limitation":10,"source_label":103},20237,"NDC 60270-209-13\nFlunixin Injection\n(flunixin meglumine injection)\n50 mg\u002FmL\nSterile",{"id":411,"kind":412,"statement":413,"species":10,"limitation":10,"source_label":91},20238,"adverse_reaction","ADVERSE REACTIONS\nIn horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of flunixin meglumine injection. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Aspen Veterinary Resources at info@aspenveterinaryresources.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",{"id":415,"kind":412,"statement":416,"species":10,"limitation":10,"source_label":103},20239,"Adverse Reactions\nIn horses, isolated reports of local reactions following intramuscular injection, particularly in\nthe neck, have been received. These include localized swelling, sweating, induration, and\nstiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections\nhave been reported in association with intramuscular use of Flunixin Meglumine\nInjection. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have\nbeen fatal, have been reported, primarily following intravenous use.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the\nSafety Data Sheet (SDS), contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us.\nFor additional information about adverse drug experience reporting for animal drugs, contact\nFDA at 1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",{"id":418,"kind":412,"statement":419,"species":10,"limitation":10,"source_label":91},20240,"ADVERSE REACTIONS\nIn horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of flunixin meglumine injection. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov\u002Freportanimalae.",{"id":421,"kind":412,"statement":422,"species":10,"limitation":10,"source_label":152},20241,"ADVERSE REACTIONS In horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of BANAMINE (flunixin meglumine injection). In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.",{"id":424,"kind":412,"statement":425,"species":10,"limitation":10,"source_label":117},20242,"ADVERSE REACTIONS\nFlunixin was mildly irritating at the injection sites. No other flunixin-related changes (adverse reactions) were noted in swine administered a 1X (2.2 mg\u002Fkg; 1.0 mg\u002Flb) dose for 9 days.\nTo report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov\u002Freportanimalae.",{"id":427,"kind":412,"statement":428,"species":10,"limitation":10,"source_label":139},20243,"Flunixin was mildly irritating at the injection sites. No other flunixin-related changes (adverse reactions) were noted in swine administered a 1 x (2.2 mg\u002Fkg; 1.0 mg\u002Flb) dose for 9 days. To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Norbrook at 1-866-591-5777. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov\u002Freportanimalae.",{"id":430,"kind":412,"statement":431,"species":10,"limitation":10,"source_label":135},20244,"ADVERSE REACTIONS: Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle.\nIn cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use of flunixin meglumine.",{"id":433,"kind":412,"statement":434,"species":10,"limitation":10,"source_label":103},20245,"To report suspected adverse drug events, for technical\nassistance or to obtain a copy of the Safety Data Sheet (SDS),\ncontact Huvepharma, Inc. at 1-877-994-4883 or\nwww.huvepharma.us. For additional information about adverse\ndrug experience reporting for animal drugs, contact FDA at\n1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.\n®Registered trademark of Huvepharma, Inc.\nManufactured for\nHuvepharma, Inc. Rev. 09-2021\nPeachtree City, GA 30269 F-2847-04",{"id":436,"kind":412,"statement":437,"species":10,"limitation":10,"source_label":103},20246,"To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.\nManufactured for\nVetTek\nBlue Springs, MO 64014",{"id":439,"kind":412,"statement":440,"species":10,"limitation":10,"source_label":130},20247,"Flunixin was mildly irritating at the injection sites. No other flunixin-related changes (adverse reactions) were noted in swine administered a 1× (2.2 mg\u002Fkg; 1.0 mg\u002Flb) dose for 9 days.",{"id":442,"kind":443,"statement":444,"species":10,"limitation":10,"source_label":122},20248,"mechanism_of_action","CLINICAL PHARMACOLOGY: Flunixin meglumine is a nonsteroidal, anti-inflammatory drug. It is a weak acid (pKa=5.82)1 which exhibits a high degree of plasma protein binding (approximately 99%).2 However, free (unbound) drug appears to readily partition into body tissues (Vss predictions range from 297 to 782 mL\u002Fkg).2-5 In cattle, elimination occurs primarily through biliary excretion.\nFlunixin persists in inflammatory tissues6 and is associated with anti-inflammatory properties which extend well beyond the period associated with detectable plasma drug concentrations.4,6 Therefore, prediction of drug concentrations based upon the estimated plasma terminal elimination half-life will likely underestimate both the duration of drug action and the concentration of drug remaining at the site of activity.\nPharmacokinetic properties of flunixin transdermal solution in cattle administered at a dose of 2.5 mg\u002Fkg, are summarized in Table 1, comparing results between animals that were allowed to self- and allo-lick vs. animals that were prevented from licking. Animals that were allowed to self- or allo-lick had lower rate and extent of absorption when compared to the animals prevented from licking. However, no dose adjustment is needed to account for the effect of licking because the substantial evidence of effectiveness was demonstrated in animals that were allowed to lick.\nTable 1. Average (+\u002F- standard deviation [SD]) PK parameters after a single administration of flunixin transdermal solution at a dose of 2.5 mg\u002Fkg in cattle that were either allowed to lick or prevented from allo- and self-licking (n = 24\u002Fgroup).\nPK parameter\nNon-licking\nLicking\nMean\n± SD\nMean\n± SD\nCmax: Maximum observed plasma concentration\nTmax: Time at which Cmax was observed\nAUC2-last: Area under the plasma concentration versus time curve measured between 2 hours and the time of the last quantifiable concentration\nT1\u002F2: Terminal elimination half-life\nCmax (ng\u002FmL)\n1496\n769\nN\u002FA\nN\u002FA\nConcentration at 2 hFirst blood level in the licking group was taken at 2 hours post-dose.\nFirst blood sample in non-licking group was taken at 0.25 hours post-dose.\n1282\n533\n1072\n353\nTmax (h)\n1.29\n0.464\nN\u002FA\nN\u002FA\nAUC2-last (ng*h\u002FmL)\n7499\n2131\n6827\n4672\nT1\u002F2 (h)\n8\n2\n9\n6\nAbsorption of flunixin transdermal solution in cattle is dependent on environmental temperature. The effect of temperature on flunixin absorption was tested in temperatures ranging from 15.3 to 20.1 °F (average low in the coldest study) to 80 to 100 °F (average high in the warmest study). Flunixin concentrations were consistently lower when the pour-on product was administered in a cold (temperature) rather than hot (temperature) environment. However, the clinical effectiveness was demonstrated over the range of environmental conditions expected under field conditions. No dose adjustments are necessary due to environmental temperature.",{"id":446,"kind":443,"statement":447,"species":10,"limitation":10,"source_label":103},20249,"Pharmacology\nFlunixin meglumine is a potent, non-narcotic, non-steroidal, analgesic agent with anti-inflammatory and anti-pyretic activity. It is significantly more potent than pentazocine, meperidine and codeine as an analgesic in the rat yeast paw test.\nHorse\n: Flunixin is four times as potent on a mg\u002Fper mg basis as phenylbutazone as measured by the reduction of lameness and swelling in the horse. Plasma half-life in horse serum is 1.6 hours following a single dose of 1.1 mg\u002Fkg. Measurable amounts are detectable in horse plasma at 8 hours post injection.\nCattle\n: Flunixin meglumine is a weak acid (pKa=5.82)1 which exhibits a high degree of plasma protein binding (approximately 99%).2 However, free (unbound) drug appears to readily partition into body tissues (Vss predictions range from 297 to 782 mL\u002Fkg.2-5 Total body water is approximately equal to 570 ml\u002Fkg).6 In cattle, elimination occurs primarily through biliary excretion.7 This may, at least in part, explain the presence of multiple peaks in the blood concentration\u002Ftime profile following IV administration.2\nIn healthy cattle, total body clearance has been reported to range from 90 to 151 mL\u002Fkg\u002Fhr.2-5 These studies also report a large discrepancy between the volume of distribution at a steady state (Vss) and the volume of distribution associated with the terminal elimination phase (Vβ). This discrepancy appears to be attributable to extended drug elimination from a deep compartment.8 The terminal half-life has been shown to vary from 3.14 to 8.12 hours.2-5\nFlunixin persists in inflammatory tissues9 and is associated with anti-inflammatory properties which extend well beyond the period associated with detectable plasma drug concentrations.4,9 These observations account for the counterclock-wise hysteresis associated with flunixin's pharmacokinetic\u002Fpharmacodynamic relationships.10 Therefore, prediction of drug concentrations based upon the estimated plasma terminal elimination half-life will likely underestimate both the duration of drug action and the concentration of drug remaining at the site of activity.",{"id":449,"kind":443,"statement":450,"species":10,"limitation":10,"source_label":117},20250,"CLINICAL PHARMACOLOGY\nFlunixin meglumine is a potent non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent that pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test.\nFlunixin is known to persist in inflammatory tissues1 and is associated with anti-inflammatory properties which extend well beyond the period associated with detectable plasma drug concentrations2. Therefore, prediction of drug concentrations based upon estimated plasma terminal elimination half-life will likely underestimate both the duration of drug action and the concentration of drug remaining at the site of activity.\nThe pharmacokinetic profiles were found to follow a 2-compartmental model, although a deep (third) compartment was observed in some animals. The mean terminal elimination half-life (β half-life) of flunixin after a single intramuscular injection of flunixin meglumine injection (2.2 mg\u002Fkg) to pigs was between 3 and 4 hours. The mean observed maximum plasma concentration was 2944 ng\u002FmL, achieved at a mean time of approximately 0.4 hours. The mean AUC(0-LOQ) was 6431 ng*hr\u002FmL. Following IM administration of flunixin, quantifiable drug concentration could be measured up to 18 hours post dose. The mean volume of distribution was 2003 mL\u002Fkg and the mean total clearance was 390 mL\u002Fhr\u002Fkg. The mean absolute bioavailability of flunixin following an intramuscular injection in the neck was 87%.",{"id":452,"kind":443,"statement":453,"species":10,"limitation":10,"source_label":135},20251,"The pharmacokinetics (PK) of florfenicol (Table 1) and flunixin (Table 2) after subcutaneous injection of RESFLOR GOLD® is described below:\nTable 1. Mean (n=28) pharmacokinetic parameters for florfenicol in cattle after a single subcutaneous administration of RESFLOR GOLD (florfenicol dose of 40 mg\u002Fkg BW).\nMean Florfenicol PK parameters in Cattle\nPK\nParameter\nAUC0-t\n(ng*hr\u002FmL)\nAUC0-inf\n(ng*hr\u002FmL)\nCmax\n(ng\u002FmL)\nTmax\n(hr)\nT½\n(hr)\nMRT0-inf\n(hr)\nMean\n242527\n247577\n11151\n6.25\n28.5\n27.3\nSD\n42741\n41391\n4194\n3.87\n9.91\n11.6\nTable 2. Mean (n=28) pharmacokinetic parameters for flunixin in cattle after a single subcutaneous administration of RESFLOR GOLD (flunixin dose of 2.2 mg\u002Fkg BW).\nMean Flunixin PK parameters in Cattle\nPK\nParameter\nAUC0-t\nAUC0-t = Area under the plasma-concentration-time curve (AUC) from time zero to the last quantifiable concentrations\n(ng*hr\u002FmL)\nAUC0-inf\nAUC0-inf = AUC from time zero to infinity\n(ng*hr\u002FmL)\nCmax\nCmax = Maximum plasma concentration\n(ng\u002FmL)\nTmax\nTmax = Time at which Cmax was observed (hr)\nT½\nT½ = Terminal elimination half-life (hr)\nMRT0-inf\nMRT0-inf = Mean residence time from time zero to infinity (hr)\nMean\n13370\n14448n=27\n1913\n1.14\n9.5\n11.4\nSDSD = Standard deviation\n4964\n5116\n791\n0.97\n3.27\n4.41",{"id":455,"kind":443,"statement":456,"species":10,"limitation":10,"source_label":152},20252,"PHARMACOLOGY Flunixin meglumine is a potent, non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test.",{"id":458,"kind":443,"statement":459,"species":10,"limitation":10,"source_label":143},20253,"The pharmacokinetics (PK) of florfenicol (Table 1) and flunixin (Table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below:",[461],{"id":462,"documentId":463,"slug":464,"name":465},987,"acpnknbmsal5y7mvh4xrb9ac","fenamates","Fenamates",[],[],[]]